Radiology deal flow is splitting in two: $8B radiopharma and 14-state mobile imaging rollups
Radiology consolidation in 2026 is widening into two operationally different tracks: very large upstream radiopharma and imaging-component deals, and regional service platforms that bring imaging capacity to hospitals via mobile units and leased equipment. Radiology Business reported Curium signed a definitive agreement to acquire Lantheus for up to $8B after earlier reports put a potential deal near $7B, while Align Capital Partners agreed to buy Boise-based Heritage Imaging, a mobile diagnostic provider serving facilities across 14 states. For health systems, the immediate impact shows up less in headlines than in procurement and staffing: vendor portfolios can change quickly after component M&A, while outsourced and mobile imaging platforms change how rural and community facilities source PET-CT, MRI, and nuclear medicine capacity. Radiology Today’s management guidance on radiology mergers points to integration discipline, physician alignment, and process as the determinants of whether consolidation translates into measurable access and throughput improvements on the ground.
- 01The same word, “consolidation,” now covers two very different buying problems: upstream supply and R&D bets (radiopharma, components) versus front-line capacity (mobile imaging and outsourced service lines).
- 02Heritage Imaging’s 14-state footprint is a concrete benchmark for how far a mobile imaging platform can spread before standardization of protocols, credentialing, and PACS/RIS interfaces becomes the real work.
- 03When deal values move from “reported” to “definitive” (as with Curium and Lantheus), procurement teams should assume faster portfolio and contracting changes, and pull forward vendor roadmap reviews tied to nuclear medicine and theranostics growth plans.
Sep 3, 2026
